C12N 2310/319
Linked by 2'-5' linkages, i.e. having a free 3'-position
Official title: linked by 2'-5' linkages, i.e. having a free 3'-position
C12N2310/319 (Linked by 2'-5' linkages, i.e. having a free 3'-position) appears on 54 US grants and 93 published applications in this corpus.
Search patents in C12N- Granted patents
- 54
- Published applications
- 93
- Assignees
- 52
- Inventors
- 172
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 9 |
| 2004 | 2 | 4 |
| 2005 | 0 | 3 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 2 | 4 |
| 2010 | 1 | 6 |
| 2011 | 1 | 5 |
| 2012 | 2 | 2 |
| 2013 | 3 | 4 |
| 2014 | 3 | 4 |
| 2015 | 2 | 3 |
| 2016 | 3 | 6 |
| 2017 | 4 | 4 |
| 2018 | 4 | 5 |
| 2019 | 3 | 4 |
| 2020 | 2 | 1 |
| 2021 | 2 | 7 |
| 2022 | 4 | 3 |
| 2023 | 0 | 8 |
| 2024 | 2 | 1 |
| 2025 | 4 | 4 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- 5′-modified carbocyclic ribonucleotide derivatives and methods of use26 May 2026US 12,636,301 B2Sanegene Bio USA Inc.
- Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions11 Nov 2025US 12,467,045 B2Board of Trustees of Southern Illinois University
- G-rich iso-RNA oligomers as aptamers20 May 2025US 12,305,172 B2Council of Scientific and Industrial Research An Indian Registered Research An Indian Registered Body Incorporated Under the Regn. of Soc. Act (Act Xxi of 1860)
- REVERSIR™ compounds4 Mar 2025US 12,241,064 B2Alnylam Pharmaceuticals, Inc.
- Modified compounds and uses thereof25 Feb 2025US 12,234,447 B2Ionis Pharmaceuticals, Inc.
- Methods and compositions for treating ctnnb1-associated disorders6 Aug 2026US 2026/0226466 A1Alnylam Pharmaceuticals, Inc.
- Methods and Compositions for the Adar-Mediated Editing of Argininosuccinate Synthetase (ASS1)16 Jul 2026US 2026/0201388 A1Korro Bio, Inc.
- Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof2 Jul 2026US 2026/0185088 A1Aligos Therapeutics, Inc.
- Threose nucleic acid antisense oligonucleotides and methods thereof11 Dec 2025US 2025/0376684 A1Hoffmann-La Roche Inc.
- Modified Compounds and Uses Thereof20 Nov 2025US 2025/0354135 A1Ionis Pharmaceuticals, Inc.
Most cited
By later US patents
- Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages537US 5,434,257 AGilead Sciences, Inc. · 1995
- Modified internucleoside linkages (II)88US 5,817,781 AGilead Sciences, Inc. · 1998
- Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides85US 5,532,130 ADyad Pharmaceutical Corporation · 1996
- Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments83US 5,886,165 AHybridon, Inc. · 1999
- Modified internucleoside linkages (II)53US 6,410,702 B1Isis Pharmaceuticals, Inc. · 2002